NCT04435028View on ClinicalTrials.gov

Ketotifen: as a Cardioprotective Agent in Breast Cancer Patients Receiving Anthracycline-containing Chemotherapy

CompletedOBSERVATIONAL

Enrollment

111

Participants

Timeline

Start Date

January 14, 2019

Primary Completion Date

August 13, 2019

Study Completion Date

August 13, 2019

Conditions

Breast CancerIron Chelation

Interventions

DRUG

Ketotifen 1 MG

Ketotifen is added to patients on anthracycline-containing chemotherapy for 6 months

Trial Locations (1)

12345

Horus University, Damietta

All Listed Sponsors

lead

Horus University

OTHER

NCT04435028 - Ketotifen: as a Cardioprotective Agent in Breast Cancer Patients Receiving Anthracycline-containing Chemotherapy | Biotech Hunter | Biotech Hunter